FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)
Yes at 76% and No at 24% on Kalshi as of 22:44 UTC on 20 Nov 2026.
If the FDA's decision on Ulixacaltamide by Praxis Precision Medicines on or before January 29, 2027 is a full approval or an accelerated approval, the market resolves to Yes.
This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
This is a single yes or no market on Kalshi in the finance category and it asks: What will the FDA's decision be on Ulixacaltamide by Praxis Precision Medicines on or before January 29, 2027? Over the last day Yes has not moved and the market shows a spread of nine points between the best bid and ask. Trading on Kalshi is due to end on 30 January 2027 and Kalshi-reported volume is 13 contracts since this finance market opened and none of it in the last day. This market is tracked by pdata.world next to twenty-four related events on Kalshi, Polymarket and Manifold including the Polymarket event titled FDA approves Retatrutide this year. Price history for this Kalshi finance market is available from pdata.world as JSON and through its MCP server.